christine.berni@accesspharma.com

www.AccessPharma.com

2600 Stemmons Freeway
Suite 176
Dallas, TX 75207
P: 214.905.5100
F: 214.905.5101


 

Research Report| Presentation Downloads:

Access Pharma: Griffin Securities 7/30/09

Access Pharma: NextWave 12/16/09

Access Pharma: January 2010 Presentation

Disclaimer

Contact Us

Access Pharma Blog

Current Articles | RSS Feed RSS Feed

Access Pharma's (ACCP) - Updated Stock Video Chart

  
  
  
  
  

accp logoACCP Stock Video Chart @ ProActive Newsroom

 

Access Pharmaceuticals, Inc. (OTCBB: ACCP) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment called MuGard that is cleared for marketing in the U.S., Europe, and other key global markets for a common side effect of some cancer treatments known as mucositis (painful sores in the mouth and GI mucosal lining).

Comments

Currently, there are no comments. Be the first to post one!
Post Comment
Name
 *
Email
 *
Website (optional)
Comment
 *

Allowed tags: <a> link, <b> bold, <i> italics

ACCP Landing Page

accp proactive